Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 (NCT04305457) | Clinical Trial Compass
TerminatedPhase 2
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19
Stopped: COVID wave passed
United States62 participantsStarted 2020-03-21
Plain-language summary
The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (SARS-Cov-2) originated in China in December 2019. At present, there are no proven interventions to prevent progression of the disease. Some preliminary data on SARS pneumonia suggest that inhaled Nitric Oxide (NO) could have beneficial effects on SARS-CoV-2 due to the genomic similarities between this two coronaviruses. In this study we will test whether inhaled NO therapy prevents progression in patients with mild to moderate COVID-19 disease.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Laboratory confirmed COVID19 infection defined with a positive RT-PCR from any specimen and/or detection of SARS-CoV-2 IgM/IgG antibodies.
✓. Hospital admission with at least one of the following:
✓. fever ≥ 36.6 °C from axillary site; or ≥ 37.2°C from oral site; or ≥ 37.6°C from tympanic or rectal site.
✓. Respiratory rate ≥ 24 bpm
✓. cough
✓. Spontaneous breathing with or without hypoxia of any degree. Gas exchange and ventilation maybe assisted by any continuous continuous airway pressure (CPAP), or any system of Non Invasive Ventilation (NIV), with Positive End-Expiratory Pressure (PEEP) ≤ 10 cmH2O.
Exclusion criteria
✕. Tracheostomy
✕. Therapy with high flow nasal cannula
✕. Any clinical contraindications, as judged by the attending physician
✕
What they're measuring
1
Number of Participants With Mild/Moderate COVID-19 Requiring Intubation and Mechanical Ventilation